Spectroscopic MRI-Guided Proton Therapy in Non-Enhancing Pediatric High-Grade Glioma
Tomography · 2023
DOI: 10.3390/tomography9020051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tomography, 2023. Verfasst von Vicki Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Proton Therapy, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Peach Bowl LegACy (BRE).
Abstract (Originalsprache)
Radiation therapy (RT) is a critical part of definitive therapy for pediatric high-grade glioma (pHGG). RT is designed to treat residual tumor defined on conventional MRI (cMRI), though pHGG lesions may be ill-characterized on standard imaging. Spectroscopic MRI (sMRI) measures endogenous metabolite concentrations in the brain, and Choline (Cho)/N-acetylaspartate (NAA) ratio is a highly sensitive biomarker for metabolically active tumor. We provide a preliminary report of our study introducing a novel treatment approach of whole brain sMRI-guided proton therapy for pHGG. An observational cohort (c1 = 10 patients) receives standard of care RT; a therapeutic cohort (c2 = 15 patients) receives sMRI-guided proton RT. All patients undergo cMRI and sMRI, a high-resolution 3D whole-brain echo-planar spectroscopic imaging (EPSI) sequence (interpolated resolution of 12 µL) prior to RT and at several follow-up timepoints integrated into diagnostic scans. Treatment volumes are defined by cMRI for c1 and by cMRI and Cho/NAA ≥ 2x for c2. A longitudinal imaging database is used to quantify changes in lesion and metabolite volumes. Four subjects have been enrolled (c1 = 1/c2 = 3) with sMRI imaging follow-up of 4–18 months. Preliminary data suggest sMRI improves identification of pHGG infiltration based on abnormal metabolic activity, and using proton therapy to target sMRI-defined high-risk regions is safe and feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30332, USA.
- Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Department of Radiology, Children's Healthcare of Atlanta, Atlanta, GA 30342, USA.
- Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
ORCID-Profile: Vicki Huang, Abinand Rejimon, Anuradha G Trivedi
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Peach Bowl LegACy (BRE)
- NIH
- pre-doctoral fellowship
Zitieren
APA
Huang, V., Rejimon, A., Reddy, K., Trivedi, A. G., Ramesh, K. K., Giuffrida, A. S., Muiruri, R., Shim, H., & Eaton, B. R. (2023). Spectroscopic MRI-Guided Proton Therapy in Non-Enhancing Pediatric High-Grade Glioma. Tomography. https://doi.org/10.3390/tomography9020051
Vancouver
Huang V, Rejimon A, Reddy K, Trivedi AG, Ramesh KK, Giuffrida AS, et al. Spectroscopic MRI-Guided Proton Therapy in Non-Enhancing Pediatric High-Grade Glioma. Tomography. 2023. doi:10.3390/tomography9020051
BibTeX
@article{Huang2023,
author = {Huang, Vicki and Rejimon, Abinand and Reddy, Kartik and Trivedi, Anuradha G and Ramesh, Karthik K and Giuffrida, Alexander S and Muiruri, Robert and Shim, Hyunsuk and Eaton, Bree R},
title = {Spectroscopic MRI-Guided Proton Therapy in Non-Enhancing Pediatric High-Grade Glioma},
journal = {Tomography},
year = {2023},
doi = {10.3390/tomography9020051}
}
EUVIMED